Merck & Co. Inc. has announced promising results from the Phase 1 KANDLELIT-001 study, which evaluated MK-1084, an investigational KRAS G12C inhibitor, in patients with advanced colorectal cancer and non-small cell lung cancer harboring KRAS G12C mutations. The study demonstrated a manageable safety profile and encouraging antitumor activity for MK-1084, both as a monotherapy and in combination with other treatments. In non-small cell lung cancer, MK-1084 in combination with KEYTRUDA showed an objective response rate $(ORR.AU)$ of 77% in untreated metastatic patients with PD-L1 expression, while as a monotherapy, it achieved an ORR of 38% in previously treated patients. The findings suggest significant potential for MK-1084 in addressing prevalent KRAS mutations in cancer, representing a promising advancement in Merck's oncology pipeline.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.